Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress
A. Melnick, S. Liang, Y. Liu, Q. Wang, N. Dean, E. Choe, N. Kunnath, G. Bodanapu, C. Mullin, F. Akter, K. Lin, B. Magnuson, S. Kumar, D. B. Lombard, A. G. Muntean, M. Ljungman, J. Sekiguchi, R. J. H. Ryan, M. Y. Chiang
Abstract
Activated Notch signaling is highly prevalent in T-cell acute lymphoblastic leukemia (T-ALL) but pan-Notch inhibitors were toxic in clinical trials. To find alternative ways to target Notch signals, we investigated Cell division cycle 73 (Cdc73), which is a Notch cofactor and component of transcriptional machinery, a potential target in T-ALL. While we confirmed previous work that CDC73 interacts with NOTCH1, we also found that the interaction in T-ALL was context-dependent and facilitated by the lymphoid transcription factor ETS1. Using mouse models, we showed that Cdc73 is important for Notch-induced T-cell development and T-ALL maintenance. Mechanistically, Cdc73, Ets1, and Notch intersect chromatin at promoters and enhancers to activate oncogenes and genes that are important for DNA repair and oxidative phosphorylation. Consistently, Cdc73 deletion in T-ALL cells induced DNA damage and impaired mitochondrial function. Our data suggests that Cdc73 might promote a gene expression program that was eventually intersected by Notch to mitigate the genotoxic and metabolic stresses of elevated Notch signaling. We also provide mechanistic support for testing inhibitors of DNA repair, oxidative phosphorylation, and transcriptional machinery. Inhibiting pathways like Cdc73 that intersect with Notch at chromatin might constitute a strategy to weaken Notch signals without directly targeting the Notch complex.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell Leukemia
O. Lancho, A. Singh, … D. Herranz·bioRxiv·May 21, 2022
- USP7 cooperates with NOTCH1 to drive the oncogenic transcriptionalprogram in T cell leukemia
P. Ntziachristos, K. Arcipowski, … J. D Crispino·bioRxiv·Jan 16, 2018
- Cannabinoid Combination Targets NOTCH1-Mutated T-ALL Through the Integrated Stress Response Pathway
E. Besser, A. Gelfand, … D. Meiri·bioRxiv·Aug 20, 2023
- Resistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia
L. Cao, G. A. Ruiz Buendia, … F. Radtke·Blood AdvancesPeer-reviewed·Oct 24, 2023
- A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia
V. da Silva-Diz, B. Cao, … D. Herranz·bioRxiv·Jun 23, 2020
- HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy
Maša Zrimšek, Kristina Draganić, … Gerda Egger·LeukemiaPeer-reviewed·Apr 2, 2025